T-cell receptor on cytotoxic T lymphocytes recognizing GRN-1201 peptide–HLA-A*02 complexes (TCR (GRN-1201-specific))

The T-cell receptor (TCR) on cytotoxic T lymphocytes (CTLs) that recognizes GRN-1201 peptide–HLA-A*02 complexes is the primary mediator of the anti-tumor activity induced by the GRN-1201 cancer vaccine. GRN-1201 is a multi-antigen peptide vaccine designed to stimulate the immune system against melanoma and non-small cell lung cancer (NSCLC) by providing four HLA-A*02-restricted peptides derived from tumor-associated antigens (TAAs) (13.2.1, 13.2.4). These peptides are processed and presented by HLA-A*02 molecules on the surface of antigen-presenting cells, where they bind to specific TCRs on naive CD8+ T cells, triggering their activation and clonal expansion into effector CTLs (13.1.1, 13.2.2). These activated CTLs then circulate and recognize the same peptide-HLA complexes on the surface of tumor cells, leading to targeted cell lysis via the release of perforins and granzymes (15.2.1). This TCR-mediated recognition is the fundamental mechanism by which GRN-1201 aims to induce a robust, specific, and durable immune response against malignancies expressing these shared antigens (12.2.1, 14.1.2).

Other names

GRN-1201-specific T-cell receptorTCR recognizing GRN-1201 peptidesT-cell receptor for HLA-A*02-restricted melanoma-specific peptidesCytotoxic T-lymphocyte receptor for GRN-1201

GRN-1201 provides four HLA-A*02-restricted peptides that are presented by HLA-A*02 on antigen-presenting cells; the T-cell receptor (TCR) on cytotoxic T lymphocytes (CTLs) recognizes these peptide-HLA complexes, leading to CTL activation, proliferation, and the subsequent targeted killing of tumor cells presenting the same antigens (13.2.2, 15.2.1).